NCT00002363已完成1 期
Study of the Safety and Effects of Two Doses of SPC3, Administered Daily Intravenously in HIV-1 Seropositive Patients
Columbia Research Laboratories2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 2
研究概览
简要总结
To assess the effects of two doses of synthetic peptide construction 3 ( SPC3 ) on HIV-1 plasma levels (as measured by RNA PCR Amplicor) and on lymphocyte subsets in patients with initial viral load above 10,000 copies/ml. To study the safety of SPC3 and the kinetics of HIV-1 plasma level changes.
详细描述
The first five patients receive SPC3 daily for 3 weeks. If that dose is tolerated, the dose is increased and given to the next 5 patients for 3 weeks. The remaining ten patients receive a dose of SPC3 based on response to the previous two dose levels. Patients are followed through day 28.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Antiretrovirals provided regimen has been stable for at least 6 weeks prior to study screening.
- •Patients must have:
- •HIV seropositivity for at least 6 months.
- •CD4 >= 100 cells/mm
- •HIV RNA PCR (Amplicor) > 10,000 copies/ml.
- •No significant active opportunistic infection or tumor at study entry.
- •FDA DISCLAIMER:
- •The FDA encourages the inclusion of females of childbearing potential in study protocols, but the sponsor of this protocol specifically excludes females of childbearing potential from this study and includes only females who are sterile. Any questions about these inclusion/
排除标准
- •should be directed to the study's contact person.
- •Prior Medication:
- •Prior antiretrovirals.
- •Exclusion Criteria
- •Co-existing Condition:
- •Patients with the following conditions are excluded:
- •Inability to communicate with investigator or deemed likely to be noncompliant on study.
- •Concurrent Medication:
- •Any drug that may interact with SPC3 (e.g., suramin).
- •Patients with the following prior condition are excluded:
- •History of relevant drug hypersensitivity.
- •Prior Medication:
- •Investigational drug within the past 4 weeks.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human SubjectsHIV InfectionsNCT00000845National Institute of Allergy and Infectious Diseases (NIAID)30
已完成
4 期
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult SubjectsMeningococcal InfectionsMeningococcal MeningitisMeningitisNCT02591290Sanofi Pasteur, a Sanofi Company60
Unknown
4 期
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV InfectedCOVID-19HIV InfectionsNCT05105295China National Biotec Group Company Limited400
已完成
2 期
APSV in Vaccinia Naive AdultsSmallpoxNCT00050518National Institute of Allergy and Infectious Diseases (NIAID)444
已完成
3 期
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)HIV-1 InfectionNCT04233216Merck Sharp & Dohme LLC35